A double - blind , placebo - controlled study of fluvoxamine in adults with <font color="red">autistic_1</font> <font color="red">disorder_1</font> <font color="red">._1</font> <font color="red">
<br>
<br>_1</font> BACKGROUND Autistic disorder is characterized by a fundamental disturbance in social interaction , impairments in communication , and a markedly restricted repertoire of activities and interests . Abnormalities in the serotonin neurotransmitter system have been identified in some persons with autism . No consistently effective and safe drugs have been developed for treating the symptoms of autism . 
<br> METHODS Thirty adults with autistic disorder completed a 12-week double - blind , placebo - controlled trial of the potent and selective serotonin uptake inhibitor fluvoxamine maleate . <font color="red">Behavioral_2</font> <font color="red">ratings_2</font> were obtained at baseline and after 4 , 8 , and 12 weeks of treatment . 
<br> RESULTS Eight ( 53% ) of 15 patients in the fluvoxamine - treated group were categorized as responders compared with none of 15 in the placebo group ( P = .001 ) . Fluvoxamine was superior to placebo in <font color="red">reducing_1</font> <font color="red">repetitive_6</font> <font color="red">thoughts_6</font> <font color="red">and_6</font> <font color="red">behavior_6</font> ( P < .001 ) , <font color="red">maladaptive_6</font> <font color="red">behavior_6</font> ( P < .001 ) , and <font color="red">aggression_6</font> ( P < .03 ) , and in <font color="red">improving_1</font> <font color="red">some_1</font> <font color="red">aspects_1</font> <font color="red">of_1</font> <font color="red">social_6</font> <font color="red">relatedness_6</font> ( P < .04 ) , especially <font color="red">language_5</font> <font color="red">usage_5</font> ( P < .008 ) . Treatment response was not correlated with <font color="red">age_1</font> <font color="red">level_1</font> <font color="red">of_1</font> <font color="red">autistic_1</font> <font color="red">behavior_1</font> <font color="red">,_1</font> or <font color="red">full_1</font> <font color="red">-_1</font> <font color="red">scale_1</font> <font color="red">IQ_1</font> <font color="red">._1</font> Other than <font color="red">mild_5</font> <font color="red">sedation_5</font> <font color="red">and_5</font> <font color="red">nausea_5</font> in a few patients , fluvoxamine was well tolerated . <font color="red">No_1</font> <font color="red">dyskinesias_5</font> <font color="red">,_5</font> <font color="red">adverse_5</font> <font color="red">cardiovascular_5</font> <font color="red">events_5</font> <font color="red">,_5</font> <font color="red">or_5</font> <font color="red">seizures_5</font> <font color="red">occurred_2</font> <font color="red">._2</font> 
<br> CONCLUSIONS Fluvoxamine is more <font color="red">effective_1</font> than placebo in the short - term treatment of the <font color="red">symptoms_1</font> <font color="red">of_1</font> <font color="red">autistic_1</font> <font color="red">disorder_1</font> in adults . Controlled studies of fluvoxamine and other potent and selective serotonin uptake inhibitors seem warranted in children and adolescents with autism .